La maladie de Parkinson en France (serveur d'exploration)

Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.

Pramipexole And NotJean-Louis Montastruc

List of bibliographic references

Number of relevant bibliographic references: 17.
Ident.Authors (with country if any)Title
000049 Omar Ouachikh [France] ; Wisam Dieb [France] ; Franck Durif [France] ; Aziz Hafidi [France]Anterior ventral tegmental area dopaminergic neurons are not involved in the motivational effects of bromocriptine, pramipexole and cocaine in drug-free rats
000104 François Viallet [France] ; Séverine Pitel [France] ; Sylvie Lancrenon [France] ; Olivier Blin [France]Evaluation of the safety and tolerability of rasagiline in the treatment of the early stages of Parkinson's disease
000252 J. P. Azulay [France]Évaluation d'un effet disease modifier dans la maladie de Parkinson : quel schéma d'étude? : MALADIE DE PARKINSON : PEUT-ON EN MODIFIER LE COURS EVOLUTIF ?
000266 P. Cesaro [France]Maladie de Parkinson : les enjeux du traitement : MALADIE DE PARKINSON : PEUT-ON EN MODIFIER LE COURS EVOLUTIF ?
000343 Werner Poewe [Autriche] ; O. Rascol [France] ; P. Barone [Italie] ; R. A. Hauser [États-Unis] ; Y. Mizuno ; M. Haaksma ; L. Salin ; N. Juhel ; A. H. V. SchapiraExtended-release pramipexole in early Parkinson disease: A 33-week randomized controlled trial
000344 A. H. V. Schapira [Royaume-Uni] ; P. Barone [Italie] ; R. A. Hauser [États-Unis] ; Y. Mizuno [Japon] ; O. Rascol [France] ; M. Busse [Allemagne] ; L. Salin [France] ; N. Juhel [France] ; Werner Poewe [Autriche]Extended-release pramipexole in advanced Parkinson disease: A randomized controlled trial
000460 Anthony H. V. Schapira [Royaume-Uni] ; Stefan Albrecht [Allemagne] ; Paolo Barone [Italie] ; Cynthia L. Comella [États-Unis] ; Michael P. Mcdermott [États-Unis] ; Yoshikuni Mizuno [Japon] ; Werner Poewe [Autriche] ; Olivier Rascol [France] ; Kenneth Marek [États-Unis]Rationale for Delayed-Start Study of Pramipexole in Parkinson's Disease: The PROUD Study
000461 Robert A. Hauser [États-Unis] ; Anthony H. V. Schapira [Royaume-Uni] ; Olivier Rascol [France] ; Paolo Barone [Italie] ; Yoshikuni Mizuno [Japon] ; Laurence Salin [France] ; Monika Haaksma [Autriche] ; Nolwenn Juhel [France] ; Werner Poewe [Autriche]Randomized, Double-Blind, Multicenter Evaluation of Pramipexole Extended Release Once Daily in Early Parkinson's Disease
000497 Olivier Rascol [France] ; Paolo Barone [Italie] ; Robert A. Hauser [États-Unis] ; Yoshikuni Mizuno [Japon] ; Werner Poewe [Autriche] ; Anthony H. V. Schapira [Royaume-Uni] ; Laurence Salin [France] ; Mandy Sohr [Allemagne] ; Catherine Debieuvre [France]Efficacy, Safety, and Tolerability of Overnight Switching from Immediate- to Once Daily Extended-Release Pramipexole in Early Parkinson's Disease
000529 22nd ECNP (European College of Neuropsychopharmacology) : d'après le e-journal en direct du congrès, Istanbul, Turquie, 12-16 septembre 2009
000627 Alan Haycox [Royaume-Uni] ; Christophe Armand [France] ; Susana Murteira [France] ; John Cochran [France] ; Clément Francois [France]Cost Effectiveness of Rasagiline and Pramipexole as Treatment Strategies in Early Parkinson's Disease in the UK Setting
000644 Joëlle Micallef [France] ; Marc Rey [France] ; Alexandre Eusebio [France] ; Christine Audebert [France] ; Frank Rouby [France] ; Elisabeth Jouve [France] ; Sophie Tardieu [France] ; Oliver Blin [France]Antiparkinsonian drug-induced sleepiness: a double-blind placebo-controlled study of L-dopa, bromocriptine and pramipexole in healthy subjects
000978 Stéphane Thobois [France]Proposed dose equivalence for rapid switch between dopamine receptor agonists in Parkinson's disease : A review of the literature
000D49 Roberto Maggio [Italie] ; Marco Scarselli [Italie] ; Francesca Novi [Italie] ; Mark J. Millan [France] ; Giovanni U. Corsini [Italie]Potent activation of dopamine D3/D2 heterodimers by the antiparkinsonian agents, S32504, pramipexole and ropinirole
000D57 Jeffrey N. Joyce [États-Unis] ; Steve Presgraves [États-Unis] ; Lynn Renish [États-Unis] ; Sabinne Borwege [États-Unis] ; Tracy Osredkar [États-Unis] ; Diane Hagner [États-Unis] ; Maria Replogle [États-Unis] ; Mateo Pazsoldan [États-Unis] ; Mark J. Millan [France]Neuroprotective effects of the novel D3/D2 receptor agonist and antiparkinson agent, S32504, in vitro against 1-methyl-4-phenylpyridinium (MPP+) and in vivo against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): a comparison to ropinirole
000F63 C. Lebrun-Frenay [France] ; M. Borg [France]Choosing the right dopamine agonist for patients with Parkinson's disease
000F80 K. Ray Chaudhuri [Royaume-Uni] ; Suvankar Pal [Royaume-Uni] ; Christine Brefel-Courbon [France]'Sleep attacks' or 'Unintended sleep episodes' occur with dopamine agonists: Is this a class effect?

Wicri

This area was generated with Dilib version V0.6.29.
Data generation: Wed May 17 19:46:39 2017. Site generation: Mon Mar 4 15:48:15 2024